MétaCan
Menu
Back to cohort
Record W7135081236 · doi:10.1093/neuped/wuaf001.225

MDB-26. Omomyc is a promising anti-MYC therapy for pediatric medulloblastoma

2025· article· en· W7135081236 on OpenAlex
Laura Escudero, Stefan Custers, Yujin Suk, Mariano F. Mariano F. Zacarías-Fluck, Magdalena Arnal, Dillon McKenna, William Maich, Daniel Mobilio, Petar Miletic, Jonathan R. Whitfield, C. Venugopal, Laura Soucek, Sheila K. Singh

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

affAt least one author lists a Canadian institution in the pinned OpenAlex snapshot.

Bibliographic record

VenueNeuro-Oncology Pediatrics · 2025
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicProtein Degradation and Inhibitors
Canadian institutionsMcMaster UniversityHamilton Health SciencesJuravinski Cancer Centre
Fundersnot available
KeywordsMedulloblastomaNeurocognitiveNeural stem cellCarcinogenesisClinical trialBrain tumorRegulatorChemotherapyCancer

Abstract

fetched live from OpenAlex

Abstract A leading cause of cancer-related mortality in children is brain cancer, with medulloblastoma (MB) being the most common malignant type. Despite scientific advances in the field, surgery, radio- and chemotherapy still represent the current standard of care (SoC). Approximately 30% of patients relapse or develop secondary tumors, and survivors present debilitating neurocognitive impairments from SoC. Novel therapeutic approaches are needed to address the existing unmet medical need. MYC is one of the most dysregulated proteins in cancer, including MB. MYC is a master regulator of cellular processes that, when overactivated, drives tumorigenesis and tumor maintenance. However, MYC has been considered undruggable until recently. Here, we investigate the use of Omomyc as a potential therapy for pediatric MB. Omomyc is a MYC dominant negative inhibitor, currently in clinical trials for adults with advanced solid tumors as OMO-103, an Omomyc-based mini-protein. We show that Omomyc selectively targets MB brain tumor initiating cells, impairing proliferation and self-renewal, while sparing the human neural stem cells. Treatment with Omomyc downregulates MYC regulated genes, cell cycle pathways, and other oncogenic pathways specific to MB. Moreover, the half-maximal inhibitory concentration required was sustained for primary and matched SoC-recurrent samples, and a significant survival advantage was observed from our preliminary results in MB patient-derived orthotopic xenograft in vivo model. Altogether, Omomyc may be a promising therapy for MB patients, particularly at recurrence.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.269
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.011
GPT teacher head0.286
Teacher spread0.275 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it